Cornerstone Pharmaceuticals raises $6 million in financing

The proceeds are to be primarily used for advancing its clinical trials in the US and Canada evaluating the safety and efficacy of its bioenergetic altered energy metabolism-directed compound (AEMD), CPI-613, in a variety of cancer types.

CPI-613 is the lead product candidate from Cornerstone’s AEMD compound platform currently being studied in human clinical trials.

Cliff Straub, vice president and CFO of Cornerstone Pharmaceuticals, said: “Raising funds in a challenging market is a strong validation of the potential value of the bioenergetic approach to targeting cancer, and of Cornerstone’s novel product candidates for cancer therapy.”